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Background: Study C210 was a Phase IIa, exploratory trial to assess the activity of telaprevir on hepatitis C virus
(HCV) early viral kinetics in treatment-naïve patients infected with genotype 4 (G4) HCV.
Methods: Patients were randomized to receive peginterferon and ribavirin alone, telaprevir monotherapy (T arm),
or telaprevir in combination with peginterferon/ribavirin (TPR arm) for 15 days, followed by a 46- or 48-week
standard treatment phase. The current analysis aimed to characterize the genotype and phenotype of HCV G4
variants emerging during telaprevir treatment.
Results: Five of the 8 (62.5%) patients in the telaprevir (T) arm had viral breakthrough (vBT) during the
investigational treatment phase (between baseline and Day 15), compared to no patients in the TPR arm. HCV G4
viral variants with a T54A/T mutation were detected in two of these patients, as well as two other patients with
detectable HCV RNA at the end of telaprevir treatment. Emergence of the T54A/T mutation was associated with a
2- to 4-fold decreased susceptibility to telaprevir. All patients with vBT during the investigational treatment phase or
with a T54A/T mutation achieved undetectable HCV RNA 12 or 24 weeks after end of treatment with subsequent
peginterferon/ribavirin treatment.
Conclusions: In this analysis in G4 HCV-infected patients, more patients in the telaprevir monotherapy arm experienced
vBT with resistant variants compared to none with telaprevir combination therapy. The most commonly selected
mutation T54A in telaprevir-treated G4 HCV patients was previously described in the context of G1 infection.
Trial registration: The trial was registered with ClinicalTrials.gov (NCT00580801).
Keywords: Genotype 4, HCV, Mutation, Resistance, Telaprevir, Viral kineticsIntroduction
Hepatitis C virus (HCV) infection is a significant global
health burden, with an estimated global prevalence of
approximately 3% [1]. HCV is classified into six different
genotypes (G1–6), each with a distinct geographic vari-
ation and responsiveness to treatment [2,3] hepatitis C
virus genotype 4 (HCV G4) makes up 20% of HCV in-
fections worldwide, but in general is relatively uncom-
mon in the US and Europe [4-6]. However, there is an
increase in HCV G4 in certain parts of Europe, probably
driven by immigration from Africa and the Middle-East,
where HCV G4 is the most common genotype [4].* Correspondence: sdmeyer@its.jnj.com
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unless otherwise stated.Telaprevir is a protease inhibitor approved for the
treatment of treatment-naïve and treatment-experienced
G1 HCV-infected adult patients with compensated liver
disease in the US and Europe [7,8]. In telaprevir phase 3
trials, sustained virologic response (SVR) rates were sig-
nificantly higher with a regimen of 12 weeks of telaprevir
in combination with either 24 or 48 weeks of pegylated
interferon/ribavirin (Peg-IFN/RBV) than with 48 weeks
of Peg-IFN/RBV alone, both in treatment-naïve and
treatment-experienced G1 HCV-infected patients [7-9].
During treatment with direct-acting antivirals (DAA)
such as telaprevir, there is the potential for selection of
preexisting viral variants with decreased susceptibility to
DAAs with a similar mechanism of action [10]. In HCV
G1 patients a consistent, subtype-dependent resistance
profile was observed in patients who did not achieve an
SVR with telaprevir-based treatment, with emergence ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of telaprevir antiviral activity in
patients infected with G4 HCV
Antiviral activity Patients infected with G4 HCV
T (N = 8) TPR (N = 8) PR (N = 8)
n (%) n (%) n (%)
Virologic responsea
By end of TVR/Pbo treatment 0 1 (12.5%) 0
By EOT 7 (87.5) 6 (75.0) 6 (75.0)
Cumulative viral breakthrough
By end of TVR/Pbo treatment 5 (62.5) 0 0
By EOT 5 (62.5) 2 (25.0) 1 (12.5)
Missing follow-up datac 1 0 0
Relapseb 1/7 (14.3) 2/6 (33.3) 1/6 (16.7)
SVR24 5 (62.5) 4 (50.0) 5 (62.5)
aHCV RNA <25 IU/mL undetectable; bn/N (%) where N = Number of patients
with undetectable HCV RNA at EOT; cPatients with undetectable HCV RNA at EOT
for which no HCV RNA measurements were available at follow-up Week 24.
EOT: End of treatment; G: genotype; HCV: Hepatitis C virus; n: number of
patients with observation; PR: Peginterferon/ribavirin arm; T: Telaprevir
monotherapy arm; T/PR: Telaprevir plus peginterferon/ribavirin arm;
SVR24: Sustained virologic response at 24 weeks after last study dose.
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R155, and A156 [11,12].
Limited in vitro data suggests that telaprevir has activ-
ity against HCV G4 [13]. HCV G4 is highly heteroge-
neous with up to 18 subtypes identified so far [4]. This
large variation in subtype can affect disease pathology
and also increase the potential for resistance to treat-
ment, making HCV G4 potentially difficult to treat
[4,10]. The current standard treatment for HCV G4 in-
fection is 48 weeks of Peg-IFN/RBV, with variable results
[4,14,15]. Overall SVR rates have reportedly been higher
for patients with HCV G4a compared to HCV G4b [15].
Patients with HCV G4 who do not achieve an SVR with
Peg-IFN/RBV currently lack other treatment options.
Study C210 was a Phase IIa trial designed to examine the
activity of telaprevir on HCV early viral kinetics in patients
with G4 HCV infection. Telaprevir was administered alone
or in combination with Peg-IFN/RBV in treatment-naïve
G4 HCV-infected patients. In this study, the in vivo intrin-
sic activity of telaprevir monotherapy against HCV G4 was
modest; HCV RNA levels decreased slowly between base-
line and Day 15 [16]. Larger, more rapid declines were re-
ported for patients who received telaprevir plus Peg-IFN/
RBV, suggesting synergy between telaprevir and Peg-IFN/
RBV against HCV G4 [16]. Treatment with telaprevir was
generally safe and well tolerated [16].
The aim of this sub-analysis of the C210 study was to
determine the genotypic and phenotypic characteris-
tics of HCV viral variants emerging in HCV G4 pa-
tients who received telaprevir alone or in combination
with Peg-IFN/RBV.
Results
Patient disposition and baseline characteristics
Patient disposition and baseline characteristics have been
reported in detail elsewhere [16]. Briefly, a total of 24 pa-
tients (eight per treatment group) were randomized and
treated. Baseline demographics and disease characteristics
were generally comparable across treatment groups.
However, there was some variation between the groups
in gender and race; the proportion of males was 50% in
peginterferon/ribavirin (PR) arm, 62.5% in the telaprevir
(T) arm, and 75% in the telaprevir in combination with
peginterferon/ribavirin (TPR) arm, and the proportion
of black patients was 25% in the T and TPR arms, and
50% in the PR arm [16]. No enrolled patients had cir-
rhosis and 54.2% had HCV RNA ≥800,000 IU/mL.
Antiviral activity in HCV G4-infected patients
A summary of the antiviral activity is shown in Table 1
and has been discussed in detail elsewhere [16]. During
the 2-week investigational treatment phase (baseline to
Day 15), viral breakthrough (vBT) occurred in 5/8 patients
(62.5%) in the T arm and in no patients in the TPR arm.During the standard treatment phase (Week 2 to end of
treatment [EOT], in which all patients received Peg-IFN/
RBV), vBT occurred in no patients in the T arm and in 2/
8 patients (25.0%) in the TPR arm (Table 1).
Median HCV RNA levels decreased in patients in the T
and TPR arm during the investigational treatment phase
(from baseline to Day 15) upon commencing telaprevir
monotherapy. However, viral levels plateaued or started to
increase (vBT) generally after Day 3 in 5/8 patients [16].
Despite this, of the five patients with vBT after 2 weeks of
telaprevir monotherapy, four achieved undetectable HCV
RNA with subsequent Peg-IFN/RBV treatment (during
the standard treatment phase) and three achieved SVR
(one patient had missing follow-up Week 24 data but had
undetectable HCV RNA at follow-up Week 12).
In addition to the five patients with vBT during tela-
previr monotherapy, the three other patients in the T
treatment group who did not meet the definition of vBT
had detectable HCV RNA at the end of the 15-day in-
vestigational phase. Of these patients, all had undetect-
able HCV RNA at EOT; two then achieved SVR and one
relapsed. Three patients in the TPR arm also had detect-
able HCV RNA at the end of the 15-day investigational
phase; all subsequently had undetectable HCV RNA at
the end of the standard treatment phase, one achieved
SVR and two relapsed.
Baseline virologic data and early viral kinetics
Baseline sequence data were available for 23 of the 24
randomized patients. The Trugene 5’NC method was
used to determine HCV genotype and subtype for study
eligibility, with the majority of subjects either infected
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ology analyses, samples were also tested for subtype with a
more accurate HCV genotyping method based on sequen-
cing of a 329-bp region within NS5B, followed by semi-
automatic blast-based alignment to reference sequences.
Based on NS5B sequencing the most common HCV G4
genotype was HCV G4a (45.8% of patients), followed by
HCV G4d (16.7%) and HCV G4c (12.5%). Subtype distri-
bution was generally similar across the treatment arms
(Table 2); 37.5% (3 patients) were infected with HCV G4a
at baseline in the T arm and 50.0% (4 patients) had HCV
G4a in the TPR arm. Two patients in the T arm had rare
genotypes not present in patients in the TPR arm: one pa-
tient had HCV G4h and one patient had HCV G4n. Of
the five patients who had vBT during the telaprevir/pla-
cebo treatment investigational phase, three had HCV G4a,
one had HCV G4c and one had HCV G4n. Regarding pa-
tients who had detectable HCV RNA viral levels at the
end of the telaprevir/placebo treatment investigational
phase, two had HCV G4d (who both achieved SVR), and
one had HCV G4h (who relapsed).
No patients with available baseline sequences had de-
tectable mutations associated with decreased susceptibil-
ity to telaprevir previously described in the HCV G1
genotype. However, a leucine (L) was found at position
36 of the HCV G4 NS3 region in these patients. A valine
(V) is generally found at this position in HCV G1 chron-
ically infected patients, while the V36L substitution con-
fers less than 3-fold reduced susceptibility to telaprevir
in G1 patients.
Phenotype data at baseline were obtained for seven pa-
tients in the T group and one patient in the TPR group.
Telaprevir fold change (FC) at baseline ranged from 2.5
to 8.9 using the replicon-based assay and from 1.7 toTable 2 Baseline subtype distribution based on NS5B
genotyping by treatment arm
HCV subtype
(NS5B)
T (N = 8) TPR (N = 8) PR (N = 8) All patients
N = 24
n (%) n (%) n (%) n (%)
4a 3 (37.5) 4 (50.0) 4 (50.0) 11 (45.8)
4c 1 (12.5) 2 (25.0) 0 3 (12.5)
4d 2 (25.0) 2 (25.0) 0 4 (16.7)
4e 0 0 1 (12.5) 1 (4.2)
4f 0 0 1 (12.5) 1 (4.2)
4h 1 (12.5) 0 0 1 (4.2)
4k 0 0 1 (12.5) 1 (4.2)
4n 1 (12.5) 0 0 1 (4.2)
Genotype unknown 0 0 1 (12.5) 1 (4.2)
N = Number of patients with data; n = Number of patients with
that observation.
HCV: Hepatitis C virus; PR: Peginterferon/ribavirin arm; T: Telaprevir
monotherapy arm; T/PR: Telaprevir plus peginterferon/ribavirin arm.11.9 using the biochemical phenotypic assay. HCV RNA
change from baseline to Day 3 versus telaprevir suscepti-
bility at baseline in the seven T patients with data avail-
able is shown in Figure 1. For patients in the T arm,
there was a correlation between the telaprevir FC at
baseline and change in HCV RNA from baseline to Day
3. However these results need to be interpreted with
caution due to the low sample size.Characterization of viral variants
With regards to the five HCV G4-infected patients in the
T group who experienced vBT during the investigational
phase (baseline to Day 15), Figure 2 shows their individual
HCV RNA profiles over time in association with geno-
typic and phenotypic data. Sequencing was obtained for
four out of these five patients. In two patients (patients 3
and 5), emergence of T54A/T, a mutation known to be as-
sociated with reduced susceptibility to telaprevir in G1,
was detected. In patient 3 (HCV G4a), T54A/T was de-
tected at the point of vBT (Day 12). In patient 5 (HCV
G4c), T54A/T was detected at a timepoint before vBT
(Day 12), along with two other mutations (L135F/L and
I170I/M). In vitro susceptibility to telaprevir was de-
creased in these two patients with emergence of these var-
iants (Figure 2). In patient 3, FC was 4.0 at baseline and
2.1 on Day 12 using the biochemical phenotypic assay and
increased from 4.7 at baseline to 15.4 at Day 12 using the
replicon-based assay. In patient 5, FC increased from 1.7
on Day 12 to 8.2 on Day 15 using the biochemical pheno-
typic assay and from 3.2 on Day 12 to 16.5 on Day 15
using the replicon-based assay. Both patients who had
vBT with emerging T54A/T mutations achieved SVR with
subsequent Peg-IFN/RBV therapy.
In the other two patients in the T treatment group who
had vBT (Patients 1 and 2), and for whom sequencing dataFigure 1 Scatter plot showing baseline telaprevir susceptibility
versus change in HCV RNA from baseline to Day 3 in patients
treated with telaprevir monotherapy. HCV RNA, hepatitis C virus
ribonucleic acid; BL, baseline; FC, fold change in IC50 value compared
to IC50 from wild-type (con 1b); IC50, 50% inhibiting concentration.
Figure 2 (See legend on next page.)
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Figure 2 Viral load profiles of individual patients in the telaprevir monotherapy arm with vBT, for both the investigational and
standard treatment phases. Panels a-e show data from Patient 1-5. HCV RNA, Hepatitis C virus ribonucleic acid; G, genotype; EOT, end of treat-
ment; TVR disc, telaprevir discontinuation; PR disc, Peginterferon/ribavirin discontinuation; FC, fold change in IC50 value compared to IC50 from
wild-type (con 1b); Rep, replicon-based phenotypic assay; Enz, biochemical –based phenotypic assay. HCV genotype based on NS5B genotyping.
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vir susceptibility were detected. However, Patient 1
had an emerging V170A/V substitution at the time of
vBT (Day 15). An increase in telaprevir FC was noted
with the biochemical assay but not the replicon assay
(Figure 2a).
A number of other amino acid changes from baseline
were identified in patients who experienced vBT in the T
or TPR group, including: V18I/V, T63I/T, I64I/M, A95A/
T/V and P129A (G4a). These mutations were not consist-
ently seen across patients and no statistical analyses were
performed due to the low number of HCV G4 comparator
sequences available from non-exposed samples in public
or in-house databases.
For the single patient with HCV G4h in the T arm who
relapsed after standard therapy, sequence analysis was not
available at the time of relapse. However, sequence analysis
of the follow-up Week 24 sample did not identify known
resistant variants.
Along with Patients 3 and 5 in the T arm who had vBT,
emergence of a T54A/T mutation was also detected at
Day 15 in a patient in the T treatment group. This patient
did not have vBT but the mutation was associated with an
2-fold increase in telaprevir FC compared to baseline
using a replicon-based phenotypic assay. One other pa-
tient in the TPR group also reported a T54A/T mutation
although this was not associated with vBT or any change
in telaprevir FC. Both these patients achieved SVR.
Paired phenotype data at baseline and time of vBT/end
of telaprevir treatment were available for eight patients in
the study. Of these, 3/4 patients with an emerging T54A/T
mutation had a 2- to 4-fold increase in telaprevir FC com-
pared with baseline according to the replicon-based pheno-
typic assay.
Discussion
Here we report the virologic characterization of variants
emerging in the Phase IIa C210 study, the first clinical trial
investigating telaprevir in treatment-naïve, chronically-
infected HCV G4 patients. Telaprevir combined with Peg-
IFN/RBV had greater antiviral activity against HCV G4
than telaprevir monotherapy or Peg-IFN/RBV alone [16].
Telaprevir monotherapy had limited antiviral activity over
15 days; HCV RNA levels decreased only slightly and five
of eight patients had vBT (no patients in the TPR group
had vBT during this time). The remaining three patients
treated with telaprevir monotherapy had detectable HCV
RNA at Day 15.As mentioned above, all vBTs in the investigational,
telaprevir treatment phase occurred in the T group.
HCV RNA levels only decreased slowly with telaprevir
monotherapy compared with combination therapy. These
findings are in line with the results of other studies inves-
tigating telaprevir monotherapy versus telaprevir plus
Peg-IFN/RBV in HCV G1, G2, and G3 patients, and show
better results with combination therapy compared to
telaprevir monotherapy to control the emergence of re-
sistant variants [10,12,17]. In this regard, 4/5 patients
with vBT after 2 weeks of telaprevir monotherapy in our
study achieved undetectable HCV RNA with subse-
quent Peg-IFN/RBV treatment and three achieved SVR
(one patient had missing follow-up Week 24 data but
had undetectable HCV RNA at follow-up week 12).
Analysis in this study focused on detecting previously
reported HCV G1 amino acid mutations in the NS3•4A
region; including single change V36A/M, T54A, R155I/
K/M/T, and A156S which have been associated with
lower level in vitro resistance to telaprevir (3- to 25-fold
increase in replicon 50% IC50), and single change
A156T/V and double change at positions V36M + R155K
which have been associated with higher level in vitro tel-
aprevir resistance (>25-fold increase in replicon IC50)
[10,18,19]. None of the 23 patients with sequences ob-
tained by population sequencing in this study had muta-
tions associated with decreased telaprevir susceptibility
at baseline, although a leucine (L) substitution in HCV
G4 patients was detected in place of a V present in HCV
G1 patients at position 36. The functional ramifications
of this substitution are as yet unknown, though the
V36L substitution in HCV G1 has been shown to exhibit
a 2-fold change in telaprevir susceptibility [12].
Sequences were available for four of the five patients
who had vBT during the investigational phase of the
study (baseline to Day 15). In two of these patients,
T54A/T emerged, which is a mutation known to moder-
ately (FC ~6) increase telaprevir resistance in patients
with G1 HCV [10]. Two other T54A/T mutations were
also detected, one in a patient in the T group who did
not have vBT but who had detectable levels of HCV
RNA at the end of telaprevir treatment, and one in a pa-
tient in the TPR group who also had detectable levels of
HCV RNA at the end of telaprevir treatment. Overall,
paired phenotype data at baseline and time of vBT or
end of telaprevir treatment indicated that the emergence
of the T54A/T mutation in this study population was as-
sociated with a 2- to 4-fold increase in telaprevir FC
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not associated with failure of subsequent Peg-IFN/RBV
treatment and all patients with a T54A/T mutation sub-
sequently achieved SVR.
Taken together, these findings suggest that vBT and the
emergence of resistant variants following telaprevir mono-
therapy had little or no impact on the efficacy of subse-
quent treatment with Peg-IFN/RBV. However, additional
data on the clinical relevance of resistance with DAAs are
required. In this regard, interim results from EXTEND, a
multinational, 3-year follow-up study of patients treated
with telaprevir-based regimens in Phase II and Phase III
clinical trials, showed that, after ceasing telaprevir treat-
ment, levels of resistant variants can rapidly decline as they
are outcompeted by other, potentially more fit wild-type
variants [20]. Additional research is needed to ascertain
whether these patients can be successfully retreated with
the same DAA class. Nevertheless, the presence of some
mutations can still be detected years later [20], and it is
therefore important to limit potential for resistant variants
[11]. The rationale for combination therapy is due to the
non-competing mechanisms of actions of the different
agents used, which means that viruses associated with re-
sistance to one class of agent are often susceptible to an-
other class [11]. This is supported by data in this study, as
no variants known to be associated with resistance to tela-
previr were detected in patients treated with TPR therapy.
Several other mutations were also detected in HCV
G4 infected patients in this study. The variant V170A
(HCV G4a) was observed in one patient at the same
time as vBT in the T arm. This mutation has been previ-
ously observed in the HCV G1 population, although not
at high frequency. It has also been linked with low-to-
moderate levels of resistance to boceprevir [10,21]. An-
other patient (HCV G4c) had three mutations detected
at the time of vBT (including I170I/M and T54A/T).
However, the importance of the combination of these
mutations is not well defined and needs to be investi-
gated further. Other mutations identified as emerging
from baseline in patients with vBT were: V18I, T63I,
I64M, A95T/V, P129A, and L135F. Due to the limited
sample size, the lack of consistency of the mutations
across patients and the scarcity of HCV G4 comparator
sequences, the relevance of these mutations is currently
not understood. Consequently, on the basis of this study,
new HCV G4-specific mutations could not be identified.
Although few mutations known to be associated with re-
duced susceptibility to telaprevir in HCV G1 were observed
in this study, this may be due to sample size limitations.
Other viral mutations that affect DAA activity in HCV G1
may also be relevant for patients with HCV G4, since active
site residues in HCV G1 and HCV G4 in NS3 protease do-
mains are similar. Genotypic polymorphisms in the HCV
NS3•4A proteases inter- and intra-genotypes are in generallocated on the protease surface, far from the telaprevir
binding site [22].
Telaprevir FC at baseline ranged from 2.5 to 8.9 using
the replicon-based assay and from 1.7 to 11.9 using the
biochemical phenotypic assay. A correlation was ob-
served between the telaprevir FC at baseline and change
in HCV RNA from baseline to Day 3. However, as men-
tioned below, this finding needs to be interpreted with
caution.
Conclusions inferred from the result of this study are
limited due to small sample size and insufficient power
to perform appropriate statistical analysis. The small
population of this study also means that discrepancies in
baseline data (i.e., gender and race) may exert an effect
on study results, along with baseline differences in HCV
G4 subtype between treatment groups. Unfortunately, se-
quencing and virologic response data could not be obtained
for some patients in this study, further compounding the
issue of small sample size. Despite these limitations, it
should be noted that the size of this study is not unusual
for an exploratory, proof-of-principle study investigat-
ing molecular consequences of antiviral activity.
In summary, the results of this study indicates that
the in vivo intrinsic activity of telaprevir monotherapy
against genotype 4 HCV is modest after 2 weeks of
treatment, and suggests synergy between telaprevir and
Peg-IFN/RBV against genotype 4 HCV compared with
Peg-IFN/RBV alone. Whether the synergy between tela-
previr and Peg-IFN/RBV translates in higher SVR rates
than Peg-IFN/RBV alone or not, needs to be further inves-
tigated. During the telaprevir/placebo treatment phase of
this study, all cases of vBT occurred with telaprevir mono-
therapy, highlighting the importance of combination TPR
therapy. Despite this, most patients who experienced vBT
with telaprevir monotherapy achieved SVR, indicating that
vBT and the emergence of resistant variants do not pre-
clude successful Peg-IFN/RBV treatment. The most com-
mon mutation selected in G4 patients during telaprevir
therapy was T54A, a mutation previously described for
telaprevir in the context of G1 infection.
Materials and methods
The methodology for the C210 exploratory study, in-
cluding full exclusion and inclusion criteria, have been
described elsewhere [16]. This study was a Phase IIa,
partially blinded, randomized, multiple-dose trial con-
ducted from January 2008 until January 2010 at a single
French center in male or female, treatment-naïve pa-
tients, aged 18–65 years, who were chronically infected
with HCV G4. The study was approved by the center’s
institutional review board and conducted in accordance
with the Declaration of Helsinki and Good Clinical Prac-
tice guidelines (CPP Ile De France VI, 10 Pavillon
Jacquart, 47 Boulevard de l’hopital, 75013 Paris, France).
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tients. The trial was registered with ClinicalTrials.gov
(NCT00580801).
Interventions
The trial consisted of a screening period of a maximum
of 6 weeks, a 2-week investigational phase, a 46- or 48-
week standard treatment phase, and a follow-up period
of 24–48 weeks. Patients were randomized in a 1:1:1 ra-
tio to one of three treatment arms: during the investiga-
tional phase, patients received telaprevir 750 mg every
8 hours (q8h) alone (T arm), telaprevir plus Peg-IFN
alfa-2a (180 μg once weekly) and weight-based RBV
1,000–1,200 mg/day (TPR arm), or placebo q8h plus
Peg-IFN/RBV (PR arm). During the standard treatment
phase, all patients received Peg-IFN/RBV for 48 weeks
(T arm) or 46 weeks (TPR and PR arms). The present
analysis focused on the T and TPR arms since the pri-
mary goal was to characterize HCV variants detected in
telaprevir-treated patients infected with G4 HCV.
Primary and secondary endpoints of this study have been
reported elsewhere [16]. Patients were considered to have
viral breakthrough vBT if they had a confirmed increase >1
log10 in HCV RNA concentration from the lowest level
reached or a confirmed value of HCV RNA >100 IU/mL in
patients whose HCV RNA had previously reached <25 IU/
mL. Patients were considered to have had a relapse when
they had confirmed detectable HCV RNA during the
follow-up period, despite having undetectable HCV RNA at
EOT. vBT and relapse were considered confirmed when re-
spective criteria were fulfilled at two or more consecutive
time points or at the last observed time point in case of trial
termination. For patients in the T arm, no confirmation of
vBT was needed during the investigational treatment phase.
SVR was defined as having undetectable HCV RNA at
EOT through to 24 weeks after the last dose of study
medication.
Virologic assessments
Samples for viral sequencing of the NS3•4A region were
obtained at baseline, Days 2, 3, 4, 8, 12, and 15, Weeks
4, 12, 24, 36, and EOT. If HCV RNA was undetectable
at EOT, then further samples were taken at Weeks 4, 8,
12, and 24. Otherwise, samples were taken at Weeks 4
and 24 after EOT. Samples were also obtained 24 weeks
after relapse was detected.
HCV RNA levels were evaluated using COBASW TaqmanW
HCV test version 2.0, with a limit of quantification of 25 IU/
mL. If an HCV RNA signal was detected at <25 IU/mL it
was reported as “<25 IU/mL detected”, if no HCV RNA was
detected in the sample it was reported as “<25 IU/mL,
target not detected”. HCV RNA “<25 IU/mL, target not
detected” is also described as undetectable HCV RNA
in the manuscript.Genotypic analyses
For virology analyses, HCV genotype and subtype were
determined based on sequencing information from the
NS5B gene (Table 2). Subtype-specific population-based
HCV NS3 amplification and sequencing protocols (Virco
BVBA, Beerse, Belgium) were performed on patient
plasma samples to determine the predominant HCV
genotype in all baseline samples, and also in post-
baseline samples from telaprevir-treated patients who
did not achieve an SVR or who had vBT. The lower limit
of detection of the sequencing assay was approximately
1,000 IU/mL HCV RNA.
Population-based analysis focused on detecting previ-
ously reported HCV G1 amino acid mutations in the
HCV G4 subtype specific NS3 region (amino acids 1–
181). This included detection of single change V36A/M,
T54A, R155I/K/M/T, A156S/T/V and double change at
positions V36M + R155K [12,19].
Phenotypic analyses
Two types of assay were used to conduct phenotypic
analyses: a biochemical assay and a transient replicon-
based assay.
Regarding the biochemical assay, selected patient-
derived NS3 (amino acid 1–181) sequences were cloned
into a modified pET11a vector and expressed using
Escherichia coli Rosetta2 (DE3) (Novagen, Madison,
WI, USA). In vitro telaprevir inhibition of NS3•4A was
determined using a fluorescence-resonance energy trans-
fer cleavage assay with retS1 peptide substrate (Anaspec,
San Jose, CA, USA). Inhibition values derived from a
series of telaprevir concentrations were used to calcu-
late the 50% inhibitory concentration (IC50) value. Fold
change in IC50 values (FC) compared with HCV wild-
type (Con1b) were also calculated.
For the transient replicon-based assay, derived prote-
ase sequences were shuttled into a G1b shuttle replicon
with the corresponding protease sequence deleted.
Pooled colonies containing several chimeric replicons
were then collected and DNA was in vitro transcribed
using a T7 MEGAscript High Yield Transcription Kit
(Ambion, Foster City, CA, USA). Purified wild-type or
replicated RNA was then transfected into human hepa-
toma Huh-7 lunet cells, and incubated in 384-well plates
containing telaprevir dilution series. After incubation, lu-
minescence based dose–response curves were used to
determine IC50 and FC was calculated as IC50 of shuttle
construct divided by IC50 of wild-type G1b replicon
(mean value of three experiments).
Statistical analyses
Because of the low number of patients infected with
HCV G4 in this study, no statistical analysis was per-
formed and data were summarized descriptively.
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